Attovia Therapeutics (NASDAQ: ATTO) has filed to raise approximately $200 million through an initial public offering of 12.5 million shares priced between $15.00 and $17.00 per share, implying a midpoint offering size of $200 million and a fully diluted market capitalization of approximately $616 million at the midpoint. The offering is being led by Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.
Attovia is a clinical-stage biotechnology company developing next-generation biologics for immune-mediated diseases using its proprietary ATTOBODY platform. Unlike many early-stage biotechnology companies built around a single drug candidate, Attovia has rapidly assembled a pipeline of internally discovered therapeutics designed to improve upon existing standards of care by targeting commercially validated immune pathways while potentially offering greater efficacy, longer dosing intervals, and improved patient convenience.
The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), commonly referred to as the "itch cytokine," for the treatment of chronic pruritic diseases including chronic pruritus, high-itch atopic dermatitis, cholestatic pruritus, and chronic kidney disease-associated pruritus. Early Phase 1 data demonstrated favorable tolerability, low immunogenicity, rapid itch relief, and pharmacokinetic characteristics that could support once-quarterly subcutaneous dosing, a potentially meaningful advantage over existing therapies. The company expects to initiate a Phase 2 study during the first half of 2027.
Beyond its lead program, Attovia is advancing ATTO-2306, a bispecific biologic targeting both IL-13 and IL-31 for atopic dermatitis and other inflammatory skin diseases, as well as ATTO-1091, a trispecific biologic targeting TL1A, IL-23, and integrin α4β7 for inflammatory bowel disease. Both candidates are currently in IND-enabling studies, with Phase 1 clinical trials expected to begin during the first half of 2027.
The company's underlying ATTOBODY platform represents a key differentiator. Built around biparatopic nanobody technology licensed from Alamar Biosciences, the platform is designed to rapidly generate highly potent mono-, bi-, and trispecific biologics capable of simultaneously targeting multiple disease pathways. Management believes this modular approach could accelerate drug discovery while improving potency, durability, and dosing convenience compared with conventional antibody therapies.
Financially, Attovia remains a pre-commercial biotechnology company investing heavily in research and development. The company reported 2025 collaboration revenue of $1.35 million, a net loss of $60.6 million, and held $132.6 million in cash, cash equivalents, and marketable securities as of March 31, 2026. Management also disclosed preliminary cash, cash equivalents, and marketable securities of approximately $115.1 million as of June 30, 2026. At the midpoint pricing assumption, the IPO is expected to generate approximately $182.4 million in net proceeds to support continued clinical development of ATTO-1310, ATTO-2306, ATTO-1091, and the broader research pipeline.
Since its founding in 2023, Attovia has raised approximately $255.8 million from leading life sciences investors including Deep Track Capital, Frazier Life Sciences, Goldman Sachs Alternatives, and venBio, providing significant institutional backing ahead of its public debut.
Attovia's investment thesis extends beyond any single drug candidate. The company's proprietary ATTOBODY platform, expanding pipeline, and focus on clinically validated immune pathways provide multiple opportunities for long-term value creation. As with most early-stage biotechnology companies, however, future valuation will largely depend on successful clinical execution, regulatory progress, and the ability to demonstrate meaningful differentiation from existing therapies.